Connect Biopharma Valuation
| CNTB Stock | USD 0.81 0.01 1.26% |
Today, the firm appears to be undervalued. Connect Biopharma shows a prevailing Real Value of $2.35 per share. The current price of the firm is $0.8101. Our model approximates the value of Connect Biopharma from analyzing the firm fundamentals such as Return On Equity of -0.18, profit margin of (0.89) %, and Current Valuation of (65.65 M) as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Connect Biopharma's valuation include:
Price Book 0.4001 | Enterprise Value | Enterprise Value Ebitda 0.1857 | Price Sales 1.8329 | Forward PE 0.7669 |
Undervalued
Today
Please note that Connect Biopharma's price fluctuation is very risky at this time. Calculation of the real value of Connect Biopharma is based on 3 months time horizon. Increasing Connect Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Connect Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Connect Stock. However, Connect Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.81 | Real 2.35 | Target 7.0 | Hype 0.8 | Naive 0.86 |
The real value of Connect Stock, also known as its intrinsic value, is the underlying worth of Connect Biopharma Company, which is reflected in its stock price. It is based on Connect Biopharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Connect Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Connect Biopharma Holdings helps investors to forecast how Connect stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Connect Biopharma more accurately as focusing exclusively on Connect Biopharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Connect Biopharma's intrinsic value based on its ongoing forecasts of Connect Biopharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Connect Biopharma's closest peers. If more than one evaluation category is relevant for Connect Biopharma we suggest using both methods to arrive at a better estimate.
Connect Biopharma Cash |
|
Connect Valuation Trend
Comparing Connect Biopharma's enterprise value against its market capitalization is a good way to estimate the value of Connect Biopharma Holdings uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Connect Biopharma Total Value Analysis
Connect Biopharma Holdings is currently anticipated to have valuation of (65.65 M) with market capitalization of 44.2 M, debt of 465 K, and cash on hands of 1.28 B. The negative valuation of Connect Biopharma may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Connect Biopharma fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(65.65 M) | 44.2 M | 465 K | 1.28 B |
Connect Biopharma Asset Utilization
One of the ways to look at asset utilization of Connect is to check how much profit was generated for every dollar of assets it reports. Connect Biopharma Holdings shows a negative utilization of assets of -0.12 percent, losing $0.001213 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Connect Biopharma Holdings shows how discouraging it operates for each dollar spent on its assets.Connect Biopharma Ownership Allocation
Connect Biopharma holds a total of 55.25 Million outstanding shares. Connect Biopharma Holdings retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Connect Biopharma Profitability Analysis
Net Loss for the year was (59.38 M) with profit before overhead, payroll, taxes, and interest of 24.12 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Connect Biopharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Connect Biopharma and how it compares across the competition.
About Connect Biopharma Valuation
The stock valuation mechanism determines Connect Biopharma's current worth on a weekly basis. Our valuation model uses a comparative analysis of Connect Biopharma. We calculate exposure to Connect Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Connect Biopharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -1.1 M | -1.2 M |
Connect Biopharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 55.1 M | |
| Forward Price Earnings | 0.7669 |
Connect Biopharma Current Valuation Indicators
Valuation refers to the process of determining the present value of Connect Biopharma Holdings and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Connect we look at many different elements of the entity such as Connect's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Connect Biopharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Connect Biopharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Connect Biopharma's worth.Complementary Tools for Connect Stock analysis
When running Connect Biopharma's price analysis, check to measure Connect Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Connect Biopharma is operating at the current time. Most of Connect Biopharma's value examination focuses on studying past and present price action to predict the probability of Connect Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Connect Biopharma's price. Additionally, you may evaluate how the addition of Connect Biopharma to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |